Repeated CBD Administration and Cannabis Outcomes
The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study
Hannah Harris
23 participants
Apr 1, 2026
INTERVENTIONAL
Conditions
Summary
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.
Eligibility
Inclusion Criteria9
- English-speaking, literate adults,
- Male or female,
- Between the ages of 18-55,
- Body Mass Index from 18.5-32.0 kg/m2,
- Not currently seeking treatment for cannabis or drug use,
- Able to provide written informed consent and perform all study procedures,
- If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
- Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
- Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.
Exclusion Criteria11
- Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
- Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \[e.g., asthma, COPD\]),
- Current or past history of major psychiatric disorder that would limit ability to participate in the study,
- Use of cannabis exclusively for medical reasons (no recreational use reported),
- Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
- Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
- Clinically significant abnormal ECG (as determined by study physician/cardiologist),
- Clinically significant abnormal laboratory findings,
- History of seizure disorder,
- Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
- Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Active Cannabidiol: Active cannabidiol (medium dose) will be administered orally for 14 days.
Description: Active Cannabidiol: Active cannabidiol (higher dose) will be administered orally for 14 days.
Active Marijuana: Active Marijuana (active inhaled cannabis) will be administered through a vaporizer once per study session day (Day 1, 7, 14) per block (3 blocks total).
Inactive/Placebo Cannabidiol: Inactive/placebo cannabidiol will be administered orally for 14 days.
Inactive/Placebo Marijuana: Experimental, non-therapeutic administration of an inactive/placebo marijuana dose will be administered through a vaporizer at each study session day (Days 1, 7, 14) per block (3 blocks total).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07434895